Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median
Autori
Rivista
Ther Adv Med Oncol
Topic
Analisi statistiche e metanalisi
Impact factor
6,852
Abstract
Abstract non disponibile
Link PubMed del paper
https://pubmed.ncbi.nlm.nih.gov/32547648/